Semaglutide

Semaglutide is a modified peptide analogue of GLP-1 designed to resist enzymatic degradation and to provide prolonged activity at the GLP-1 receptor. It is widely studied in metabolic research due to well characterised incretin receptor pharmacology and robust endocrine signalling effects. Mechanistic work focuses on GLP-1 receptor signalling that influences glucose-dependent insulin secretion, glucagon regulation, gastric motility pathways, and central satiety signalling. Research studies track endocrine biomarkers and metabolic readouts to characterise receptor kinetics, signalling persistence, and integrated effects on energy intake and glycaemic regulation pathways.

‍

‍

‍

‍

‍

‍

‍

‍

‍

‍

‍